Second, several studies examining ACE inhibitor use and cancer risk have included prevalent drug users, which can introduce bias because prevalent users are “survivors” of the early period of pharmacotherapy and because covariates at study entry can be influenced by prior medication use [12,17–20]. Here, ACE is linked to cancer.